Eupraxia Pharmaceuticals (EPRX) Cash From Financing

EPRX Annual CFF

$15.56 M
+$7.26 M+87.46%

31 December 2023

EPRX Cash From Financing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

EPRX Quarterly CFF

-$4.60 M
-$101.90 K-2.26%

01 September 2024

EPRX Quarterly CFF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

EPRX TTM CFF

$13.99 M
-$20.89 M-59.88%

01 September 2024

EPRX TTM CFF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

EPRX Cash From Financing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+87.5%-2.3%-59.9%
3 y3 years+3427.5%-4478.4%-64.3%
5 y5 years+280.9%-530.6%+2017.8%

EPRX Cash From Financing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-60.9%+87.5%-119.9%at low-68.2%+162.2%
5 y5-year-60.9%+3427.5%-114.4%at low-68.2%+2017.8%
alltimeall time-60.9%+3427.5%-114.4%at low-68.2%+2017.8%

Eupraxia Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sept 2024
-
-$4.60 M(+2.3%)
$13.99 M(-59.9%)
June 2024
-
-$4.50 M(-119.4%)
$34.88 M(-20.7%)
Mar 2024
-
$23.15 M(<-9900.0%)
$43.97 M(+109.3%)
Dec 2023
$15.56 M(+87.5%)
-$59.00 K(-100.4%)
$21.01 M(-5.6%)
Sept 2023
-
$16.29 M(+254.8%)
$22.25 M(+316.9%)
June 2023
-
$4.59 M(+2259.1%)
$5.34 M(-51.6%)
Mar 2023
-
$194.60 K(-83.5%)
$11.03 M(+2.1%)
Dec 2022
$8.30 M
-
-
Dec 2022
-
$1.18 M(-287.9%)
$10.80 M(+13.4%)
Sept 2022
-
-$626.70 K(-106.1%)
$9.52 M(+1.9%)
June 2022
-
$10.29 M(<-9900.0%)
$9.34 M(+31.6%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$36.20 K(-64.0%)
$7.10 M(-81.9%)
Dec 2021
$39.81 M(-8612.5%)
-$100.50 K(-87.5%)
$39.15 M(+0.1%)
Sept 2021
-
-$805.00 K(-110.0%)
$39.10 M(-2.0%)
June 2021
-
$8.04 M(-74.9%)
$39.90 M(+23.7%)
Mar 2021
-
$32.01 M(<-9900.0%)
$32.25 M(-6664.1%)
Dec 2020
-$467.70 K(-108.4%)
-$149.40 K(+1892.0%)
-$491.30 K(+43.7%)
Sept 2020
-
-$7500.00(-101.9%)
-$341.90 K(+2.2%)
June 2020
-
$395.30 K(-154.2%)
-$334.40 K(-54.2%)
Mar 2020
-
-$729.70 K
-$729.70 K
Dec 2019
$5.57 M(+36.4%)
-
-
Dec 2018
$4.09 M(-44.1%)
-
-
Dec 2017
$7.30 M
-
-

FAQ

  • What is Eupraxia Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Eupraxia Pharmaceuticals?
  • What is Eupraxia Pharmaceuticals annual CFF year-on-year change?
  • What is Eupraxia Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Eupraxia Pharmaceuticals?
  • What is Eupraxia Pharmaceuticals quarterly CFF year-on-year change?
  • What is Eupraxia Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Eupraxia Pharmaceuticals?
  • What is Eupraxia Pharmaceuticals TTM CFF year-on-year change?

What is Eupraxia Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of EPRX is $15.56 M

What is the all time high annual CFF for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals all-time high annual cash flow from financing activities is $39.81 M

What is Eupraxia Pharmaceuticals annual CFF year-on-year change?

Over the past year, EPRX annual cash flow from financing activities has changed by +$7.26 M (+87.46%)

What is Eupraxia Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of EPRX is -$4.60 M

What is the all time high quarterly CFF for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals all-time high quarterly cash flow from financing activities is $32.01 M

What is Eupraxia Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, EPRX quarterly cash flow from financing activities has changed by -$101.90 K (-2.26%)

What is Eupraxia Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of EPRX is $13.99 M

What is the all time high TTM CFF for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals all-time high TTM cash flow from financing activities is $43.97 M

What is Eupraxia Pharmaceuticals TTM CFF year-on-year change?

Over the past year, EPRX TTM cash flow from financing activities has changed by -$20.89 M (-59.88%)